Lalita Dwivedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lalita Dwivedi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Kamran
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA
1 shared publication - Nishant Singh
Cell and Gene Therapy Division Absorption System, Exton, PA 19341, USA
1 shared publication - Sarah Naiyer
School of Environmental Sciences, Jawaharlal Nehru University, New Delhi, India
1 shared publication - Swastik Phulera
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, USA
1 shared publication - Vijay Mohan
School of Biosciences & Technology, Galgotias University, Greater Noida, India
1 shared publication
Latest Publications
- Open Access
Role of Transcription Factor BEND3 and Its Potential Effect on Cancer Progression
BEND3 is a transcription factor that plays a critical role in the regulation of gene expression in mammals. While there is limited research on the role of BEND3 as a tumor suppressor or an oncogene and its potential role in cancer therapy is still emerging, several studies suggest that it may be involved in both the processes. Its interaction and regulation with multiple other factors via p21 have already been reported to play a significant role in cancer development, which serves as an indication of its potential role in oncogenesis. Its interaction with chromatin modifiers such as NuRD and NoRC and its role in the recruitment of polycomb repressive complex 2 (PRC2) are some of the additional events indicative of its potential role in cancer development. Moreover, a few recent studies indicate BEND3 as a potential target for cancer therapy. Since the specific mechanisms by which BEND3 may contribute to cancer progression are not yet fully elucidated, in this review, we have discussed the possible pathways BEND3 may take to serve as an oncogenic driver or suppressor.
Open AccessRole of Transcription Factor BEND3 and Its Potential Effect on Cancer Progression
BEND3 is a transcription factor that plays a critical role in the regulation of gene expression in mammals. While there is limited research on the role of BEND3 as a tumor suppressor or an oncogene and its potential role in cancer therapy is still emerging, several studies suggest that it may be involved in both the processes. Its interaction and regulation with multiple other factors via p21 have already been reported to play a significant role in cancer development, which serves as an indication of its potential role in oncogenesis. Its interaction with chromatin modifiers such as NuRD and NoRC and its role in the recruitment of polycomb repressive complex 2 (PRC2) are some of the additional events indicative of its potential role in cancer development. Moreover, a few recent studies indicate BEND3 as a potential target for cancer therapy. Since the specific mechanisms by which BEND3 may contribute to cancer progression are not yet fully elucidated, in this review, we have discussed the possible pathways BEND3 may take to serve as an oncogenic driver or suppressor.